October 2006 in “Urology” The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
August 2004 in “Medisch-Farmaceutische Mededelingen” Long-term use of finasteride may cause breast cancer in men.
2 citations
,
August 2016 in “Experimental Dermatology” Finasteride treats baldness but may cause lasting sexual side effects.
8 citations
,
June 1995 in “Helvetica Chimica Acta” Compound 15a was effective in inhibiting 5α-reductase.
May 2024 in “Journal of clinical medicine” Spironolactone is safe for treating female hair loss, but the safety of other drugs is uncertain.
August 2018 in “Daehan binyogi jong-yang haksulji” Taking sildenafil and finasteride together is safe and improves urinary and sexual symptoms in BPH patients.
8 citations
,
January 1996 in “Gynecological Endocrinology” Cyproterone acetate is the preferred treatment for women's hyperandrogenism when estrogen/progestogen use is safe.
July 2024 in “Forum Dermatologicum” Topical treatments for hair loss can be effective but need careful safety evaluation.
2 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Dutasteride more effective than finasteride for hair growth; SM04554 safe and potentially effective for hair loss.
April 2017 in “The Journal of urology/The journal of urology” Long-term use of certain prostate drugs can worsen erectile dysfunction by changing penile tissue, especially in rats with high blood pressure.
23 citations
,
April 1999 in “The Journal of Clinical Endocrinology and Metabolism” All treatments reduce hair growth; low dose flutamide most effective with fewer side effects.
1 citations
,
December 1989 in “PubMed”
May 2026 in “Frontiers in Pharmacology” Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
179 citations
,
March 2005 in “British Journal of Dermatology” Oral antiandrogens effectively treat female hair loss, with better results in higher hair loss grades.
42 citations
,
December 2015 in “International Journal of Clinical Pharmacology and Therapeutics” The 0.25% finasteride solution, when applied once a day, effectively reduces scalp DHT, potentially minimizing sexual side-effects linked to a systemic DHT reduction.
February 2026 in “Journal of Dermatological Treatment” CG2001 is safe and well-tolerated for treating hair loss, with fewer side effects than oral finasteride.
12 citations
,
January 1998 in “Drug safety” Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.
25 citations
,
November 1979 in “International Journal of Dermatology” Androgens affect skin conditions like acne and hair loss through specific biochemical pathways.
3 citations
,
October 1993 in “Endocrinology”
11 citations
,
January 1991 in “Urology” New hormonal treatments for enlarged prostate show promise for safer, effective non-surgical options.
13 citations
,
August 2007 in “Bioorganic & medicinal chemistry letters” A new compound effectively inhibits human 5α-reductase 1.
March 2024 in “Cleveland Clinic journal of medicine” Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
36 citations
,
November 2020 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
22 citations
,
March 2003 in “Steroids” PM-9 and finasteride effectively inhibit the enzyme that converts testosterone to DHT.
1 citations
,
January 2002 in “Yaoxue jinzhan” Finasteride reduces sperm count and affects male reproductive function, while Epristeride does not.
September 2024 in “Indian Journal of Dermatology Venereology and Leprology” Mesotherapy with bicalutamide has limited effectiveness for female hair loss.
Baicalin may effectively treat hair loss by inhibiting 5α-reductase.
7 citations
,
May 2015 in “Journal of The American Academy of Dermatology” Finasteride helps treat frontal fibrosing alopecia, improving or stabilizing the condition in many patients.